HeartBeam (NASDAQ: BEAT) announced on December 10, 2025, that it received FDA 510(k) clearance for its 12-lead ECG synthesis software for arrhythmia assessment after successfully appealing a prior Not Substantially Equivalent (NSE) determination. The clearance marks a significant milestone for the medical technology company, which focuses on transforming cardiac care through personalized insights.
The patented cable-free technology captures cardiac electrical signals in three non-coplanar dimensions to generate a synthesized 12-lead ECG that can be reviewed remotely by a board-certified cardiologist. This capability enables patients to capture meaningful ECG data wherever symptoms occur, potentially improving access to cardiac monitoring outside clinical settings.
With clearance in hand, HeartBeam plans a limited U.S. launch in early 2026 with select cardiology groups. The company is also advancing programs in heart attack detection, development of an on-demand 12-lead extended wear patch, and the creation of AI-powered screening and prediction algorithms driven by longitudinal data from its 3D ECG platform. According to the company's announcement, the HeartBeam System is intended for adult patients in clinical or home settings, recording a 3-lead ECG from five electrodes. The synthesized 12-lead ECG output is cleared for manual assessment of normal sinus rhythm and specific non-life-threatening arrhythmias, including sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. The software does not conduct cardiac analysis and is not intended to replace a standard 12-lead ECG.
The FDA clearance follows a previous December 2024 clearance for the 3D ECG technology for arrhythmia assessment. HeartBeam holds over 20 issued patents related to technology enablement. The company's platform is designed for portable devices that can be used wherever the patient is, aiming to deliver actionable heart intelligence to physicians for identifying cardiac health trends and acute conditions outside of medical facilities.
For additional information, visit HeartBeam.com. The full press release is available at https://ibn.fm/36RSg. The latest news and updates relating to BEAT can be found in the company’s newsroom at https://ibn.fm/BEAT.
